vrc
singlesit
phase
open
label
studi
examin
safeti
toler
immunogen
investig
dna
vaccin
one
mar
express
gp
marv
angola
strain
gp
ebo
express
wt
gp
ebov
gp
z
sudv
gp
healthi
adult
age
year
studi
conduct
nih
clinic
center
vrc
nation
institut
allergi
infecti
diseas
niaid
nation
institut
health
nih
bethesda
maryland
clinicaltrialsgov
studi
review
approv
niaid
institut
review
board
us
depart
health
human
servic
human
experiment
guidelin
conduct
clinic
research
follow
subject
gave
written
inform
consent
particip
schema
studi
shown
figur
studi
group
random
approv
proceed
mar
dna
vaccin
receiv
approv
proceed
ebo
wt
dna
vaccin
owe
delay
receiv
preclin
data
ebo
wt
dna
vaccin
thu
group
fulli
enrol
first
receiv
mar
dna
vaccin
later
group
enrol
receiv
ebo
wt
dna
vaccin
subject
per
day
administ
vaccin
first
inject
group
safeti
data
week
inject
review
protocol
safeti
review
team
continu
enrol
group
dose
vaccin
administ
ml
intramuscular
inject
deltoid
muscl
use
biojector
needlefre
inject
manag
system
bioject
group
immun
seri
prime
regimen
option
singledos
homolog
booster
schedul
prime
seri
target
studi
day
within
permit
window
base
result
preclin
immunogen
data
avail
vrc
studi
began
option
homolog
booster
dose
week
later
offer
subject
complet
inject
remain
clinic
followup
laboratori
clinic
evalu
complet
schedul
studi
visit
local
system
reactogen
selfreport
subject
use
diari
card
vaccin
clinic
assess
laboratori
evalu
creatinin
alanin
aminotransferas
complet
blood
cell
count
prothrombin
time
partial
thromboplastin
time
complet
schedul
studi
visit
advers
event
report
entir
durat
studi
code
use
medic
dictionari
regulatori
activ
grade
sever
use
divis
aid
tabl
grade
sever
advers
event
decemb
subject
follow
safeti
immunogen
week
week
receipt
option
fourth
studi
inject
ebo
plasmid
dna
vaccin
mar
plasmid
dna
vaccin
develop
vrc
ebo
plasmid
dna
vaccin
manufactur
vrcniaid
vaccin
pilot
plant
oper
leido
frederick
maryland
mar
plasmid
dna
vaccin
produc
althea
technolog
san
diego
california
manufactur
good
manufactur
practic
condit
mar
vaccin
consist
singl
close
circular
plasmid
dna
macromolecul
plasmid
vrc
design
express
wt
gp
marv
angola
strain
genbank
access
ebo
vaccin
compos
plasmid
combin
equal
concentr
milligram
per
millilit
amino
acid
sequenc
gp
antigen
express
ident
wt
gp
ebolaviru
plasmid
vrc
express
gp
gene
sudv
strain
genbank
access
vrc
express
gp
gene
ebov
strain
genbank
access
wt
gp
insert
codon
modifi
optim
antigen
express
human
cell
plasmid
vaccin
incap
replic
human
cell
vrc
construct
plasmid
contain
complementari
dna
use
subclon
wt
gp
gene
insert
cmvr
plasmid
dna
express
vector
cmvr
express
vector
test
previou
clinic
trial
dna
plasmid
vaccin
human
immunodefici
viru
west
nile
viru
sever
acut
respiratori
syndrom
avian
influenza
conduct
vrc
dna
plasmid
produc
master
cell
bank
use
plasmid
dna
transform
commerci
avail
strain
escherichia
coli
produc
largevolum
cultur
yield
mass
quantiti
plasmid
dna
bacteri
cell
growth
depend
cellular
express
kanamycin
resist
protein
encod
plasmid
dna
growth
bacteri
cell
bulk
plasmid
drug
substanc
filter
formul
phosphatebuff
salin
steril
liquid
inject
dosag
form
intramuscular
inject
end
point
titer
antibodi
direct
mar
gp
ebo
gp
antigen
z
measur
throughout
studi
serial
dilut
analyz
duplic
pre
postvaccin
time
point
mean
raw
optic
densiti
valu
postvaccin
time
point
correct
volunt
dilutionmatch
sampl
end
point
titer
calcul
dilut
serum
concentr
gave
backgroundcorrect
optic
densiti
read
titer
consid
posit
result
primari
time
point
week
third
fourth
studi
inject
peptid
amino
acid
length
overlap
correspond
vaccin
insert
mar
gp
ebo
gp
antigen
z
synthes
puriti
confirm
highperform
liquid
chromatographi
vaccineinduc
tcell
respons
detect
enzymelink
immunospot
assay
elispot
follow
modif
method
describ
elsewher
peripher
blood
mononuclear
cell
pbmc
stimul
overnight
peptid
triplic
well
densiti
cell
per
well
commerci
avail
elispot
plate
mabtech
use
color
develop
biotinyl
interferon
ifn
detect
antibodi
peroxidas
solut
ethylcarbazol
substrat
solut
plate
air
dri
hour
spot
quantit
ctl
elispot
imag
analyz
cellular
technolog
result
express
mean
spotform
cell
per
million
pbmc
posit
respons
occur
background
subtract
number
spot
per
cell
spotform
cell
per
million
pbmc
mean
greater
mean
neg
stimul
sampl
vaccineinduc
tcell
respons
detect
intracellular
cytokin
stain
follow
modif
method
describ
elsewher
antibodi
bd
bioscienc
unless
otherwis
state
includ
cyanin
dye
phycoerythrin
pe
cyanin
dye
pe
alexa
reametrix
allophycocyanin
apc
fluorescein
isothiocyan
fitc
petexa
beckman
coulter
cyanin
dye
apc
blue
aqua
blue
cell
stain
aqua
blue
room
temperatur
minut
follow
immedi
stain
surfac
marker
anoth
minut
cell
wash
twice
permeabil
cytofixcytoperm
reagent
bd
per
well
incub
wash
twice
permwash
bd
intracellular
cytokin
stain
interleukin
tumor
necrosi
factor
total
per
well
room
temperatur
minut
follow
wash
permwash
cell
resuspend
paraformaldehyd
store
hour
flow
cytometr
analysi
multiparamet
flow
cytometr
analysi
perform
lsrii
flow
cytomet
bdi
event
acquir
result
analyz
use
flowjo
softwar
version
tree
star
softwar
gate
strategi
use
clinic
test
posit
respons
occur
fisher
exact
test
tabl
consist
posit
neg
cell
peptid
neg
control
p
valu
percentag
posit
cell
peptid
minu
percentag
posit
cell
neg
control
background
subtract
percentag
exce
combin
cell
popul
cytokin
except
tumor
necrosi
factor
threshold
measur
neutral
antibodi
elicit
vaccin
assess
describ
elsewher
brief
ebov
marv
gpspecif
neutral
antibodi
assess
use
singleround
infect
assay
ebov
marv
gppseudotyp
lentivirus
respect
contain
luciferas
report
gene
deriv
cell
use
infect
target
incub
plate
day
infect
pseudoviru
presenc
dilut
subject
serum
sampl
ebov
marv
gppseudotyp
lentivir
virion
produc
describ
elsewher
pre
postimmun
serum
sampl
test
indic
figur
legend
cell
lyse
hour
infect
assay
luciferas
assay
system
promega
use
victor
plate
reader
perkinelm
detect
luciferas
activ
posit
respons
rate
comput
along
exact
confid
interv
ci
binomi
distribut
magnitud
antibodi
respons
geometr
mean
ci
base
lognorm
distribut
report
wilcoxon
sign
rank
test
use
compar
antibodi
respons
time
point
within
group
total
subject
enrol
june
june
tabl
includ
demograph
data
regard
sex
age
race
ethnic
bodi
mass
index
educ
level
enrol
subject
complet
vaccin
seri
one
subject
group
discontinu
vaccin
per
protocol
requir
studi
vaccin
owe
medic
need
licens
vaccin
subject
group
lost
followup
vaccin
vaccin
well
toler
seriou
advers
event
coagul
paramet
studi
subject
close
monitor
per
protocol
owe
theoret
concern
gpmediat
cytopatholog
prothrombin
time
partial
thromboplastin
time
complet
cell
blood
count
evalu
baselin
throughout
studi
laboratori
clinic
coagul
abnorm
detect
local
system
solicit
reactogen
tabl
gener
mild
group
similar
seen
previou
studi
dna
vaccin
construct
one
subject
report
moder
local
reaction
report
moder
system
reaction
two
advers
event
mild
transient
lightheaded
mild
pyuria
assess
possibl
relat
vaccin
one
advers
event
mild
superfici
lesion
inject
site
resolv
without
treatment
assess
definit
relat
studi
vaccin
base
tempor
relationship
biolog
plausibl
ebo
mar
specif
antibodi
respons
detect
enzymelink
immunosorb
assay
four
week
third
vaccin
subject
group
test
posit
gp
antibodi
group
test
posit
gp
test
posit
gp
z
frequenc
respons
decreas
time
week
third
vaccin
subject
posit
gp
gp
none
posit
gp
z
seven
subject
group
group
receiv
option
fourth
vaccin
homolog
boost
studi
week
four
week
fourth
vaccin
subject
posit
gp
gp
gp
z
week
boost
group
sustain
posit
respons
gp
group
sustain
posit
respons
gp
gp
z
cumul
gpspecif
respons
rate
studi
gp
gp
gp
z
magnitud
enzymelink
immunosorb
assay
titer
peak
week
third
vaccin
decreas
next
week
geometr
mean
titer
gp
gp
gp
z
week
third
vaccin
ci
ci
ci
respect
decreas
close
baselin
level
four
week
fourth
vaccin
geometr
mean
titer
gp
gp
gp
z
increas
ci
ci
ci
respect
figur
antibodi
respons
boost
fourth
dna
vaccin
administr
fourth
homolog
dna
vaccin
boost
interv
week
demonstr
boost
wane
antibodi
respons
near
peak
level
gp
gp
z
neutral
antibodi
activ
assess
report
viru
assay
result
shown
figur
group
baselin
preimmun
third
fourth
dna
vaccin
signific
mar
neutral
activ
observ
lowlevel
ebov
neutral
activ
mean
observ
fourth
vaccin
significantli
improv
compar
preimmun
serum
sampl
third
vaccin
mar
ebo
gpspecif
tcell
respons
seen
antigen
group
intracellular
cytokin
stain
week
third
dna
vaccin
tcell
respons
detect
gp
subject
gp
gp
z
week
still
tcell
respons
gp
gp
gp
z
four
week
fourth
dna
vaccin
frequenc
similar
gp
gp
gp
z
figur
tcell
respons
detect
less
frequent
tcell
respons
four
week
third
vaccin
tcell
respons
detect
subject
gp
detect
gp
gp
z
four
week
fourth
vaccin
frequenc
measur
tcell
respons
boost
subject
gp
gp
z
although
none
seen
gp
gpspecif
tcell
respons
also
assess
elispot
baselin
schedul
interv
throughout
studi
four
week
third
dna
vaccin
gpspecif
tcell
respons
present
frequenc
gp
gp
gp
z
week
subject
posit
gp
posit
gp
posit
gp
z
four
week
fourth
vaccin
frequenc
tcell
respons
increas
gp
gp
gp
z
indic
slight
boost
tcell
respons
fourth
dna
vaccin
current
avail
effect
vaccin
therapi
filovirus
effect
vaccin
would
key
prevent
health
measur
limit
spread
infect
protect
healthcar
worker
militari
troop
contain
natur
outbreak
first
clinic
trial
report
ebolaviru
wt
gp
construct
first
report
marburgviru
vaccin
clinic
trial
shown
elsewher
earliergener
genebas
construct
safe
immunogen
includ
dna
vaccin
ebo
transmembranedelet
gp
vector
encod
ebo
gp
contain
point
mutat
nonhuman
primat
studi
clearli
demonstr
fulllength
wt
gp
construct
safe
protect
cynomolg
macaqu
wt
gp
consid
antigen
like
induc
protect
antibodi
tcell
respons
phase
studi
vrc
ebo
mar
wt
gp
vaccin
well
toler
wt
gp
construct
evalu
current
studi
immunogen
induc
humor
tcell
respons
gp
immunogen
insert
also
saw
administr
fourth
dose
dna
homolog
boost
improv
otherwis
wane
antibodi
titer
tcell
respons
known
dna
provid
prime
respons
numer
antigen
typic
protein
potent
vector
boost
prolong
boost
interv
improv
overal
effect
dna
prime
report
uniqu
homolog
dna
vaccin
induc
demonstr
boost
preexist
memori
b
cell
current
trial
antibodi
respons
domin
immun
respons
tcell
respons
frequent
respons
induct
tcell
respons
vaccin
signific
recent
nonhuman
primat
studi
suggest
tcell
respons
play
import
role
protect
induc
ebo
gp
construct
vaccin
known
import
effici
viral
clearanc
studi
vrc
demonstr
wt
gp
dna
vaccin
ebolaviru
marburgviru
safe
immunogen
human
result
studi
pave
way
evalu
candid
vaccin
first
clinic
trial
candid
ebolaviru
marburgviru
vaccin
africa
phase
ib
clinic
trial
evalu
vaccin
open
accrual
kampala
uganda
interim
safeti
analysi
vrc
studi
success
evalu
dna
vaccin
target
ebolaviru
marburgviru
report
provid
opportun
explor
wt
filoviru
gp
antigen
deliveri
vaccin
platform
greater
immunogen
potenti
protect
immun
result
guid
filoviru
vaccin
research
develop
also
provid
import
generaliz
data
regard
dnabas
prime
boost
human
